Found: 6
Select item for more details and to access through your institution.
Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
- Published in:
- 2019
- By:
- Publication type:
- Correction Notice
The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2020, p. 1, doi. 10.1177/1758835920973130
- By:
- Publication type:
- Article
Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
- Published in:
- Breast Cancer Research & Treatment, 2017, v. 165, n. 3, p. 573, doi. 10.1007/s10549-017-4358-6
- By:
- Publication type:
- Article
Complete Clinical Response in Locally Advanced Metastatic de novo Breast Cancer after Front-Line Treatment with Ribociclib/Letrozole within the RIBANNA Study.
- Published in:
- Breast Care, 2020, v. 15, n. 3, p. 289, doi. 10.1159/000502565
- By:
- Publication type:
- Article
Differential impact of prognostic parameters in hormone receptor–positive lobular breast cancer.
- Published in:
- Cancer (0008543X), 2020, v. 126, n. 22, p. 4847, doi. 10.1002/cncr.33104
- By:
- Publication type:
- Article